CN105873569B - 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体 - Google Patents

用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体 Download PDF

Info

Publication number
CN105873569B
CN105873569B CN201480072258.0A CN201480072258A CN105873569B CN 105873569 B CN105873569 B CN 105873569B CN 201480072258 A CN201480072258 A CN 201480072258A CN 105873569 B CN105873569 B CN 105873569B
Authority
CN
China
Prior art keywords
sirna
ncp
cisplatin
lipid
porphyrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480072258.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105873569A (zh
Inventor
林文斌
何春柏
刘德敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
University of North Carolina at Chapel Hill
Original Assignee
University of Chicago
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, University of North Carolina at Chapel Hill filed Critical University of Chicago
Publication of CN105873569A publication Critical patent/CN105873569A/zh
Application granted granted Critical
Publication of CN105873569B publication Critical patent/CN105873569B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201480072258.0A 2013-11-06 2014-11-06 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体 Active CN105873569B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900698P 2013-11-06 2013-11-06
US61/900,698 2013-11-06
PCT/US2014/064388 WO2015069926A1 (en) 2013-11-06 2014-11-06 Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers

Publications (2)

Publication Number Publication Date
CN105873569A CN105873569A (zh) 2016-08-17
CN105873569B true CN105873569B (zh) 2020-07-28

Family

ID=53042088

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480072258.0A Active CN105873569B (zh) 2013-11-06 2014-11-06 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体

Country Status (5)

Country Link
US (2) US10517822B2 (cg-RX-API-DMAC7.html)
EP (1) EP3065713B1 (cg-RX-API-DMAC7.html)
JP (2) JP6590802B2 (cg-RX-API-DMAC7.html)
CN (1) CN105873569B (cg-RX-API-DMAC7.html)
WO (1) WO2015069926A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US11872311B2 (en) 2011-07-08 2024-01-16 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
US10118169B2 (en) 2014-03-28 2018-11-06 The University Of Chicago Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis
WO2015149072A1 (en) 2014-03-28 2015-10-01 The University Of Chicago Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US10206871B2 (en) 2014-10-14 2019-02-19 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
AU2015230812A1 (en) * 2015-09-25 2017-04-13 The University Of Sydney Treatment and prevention of adrenocortical carcinoma
US10953393B2 (en) 2015-10-12 2021-03-23 The University Of Chicago Stabilization of active metal catalysts at metal-organic framework nodes for highly efficient organic transformations
WO2017192544A1 (en) 2016-05-02 2017-11-09 Massachusetts Institute Of Technology AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi
KR20190040257A (ko) 2016-08-18 2019-04-17 더 유니버서티 오브 시카고 고효율 유기 변환을 위한 금속 산화물-지지된 지구에 풍부한 금속 촉매
WO2018067431A1 (en) * 2016-10-03 2018-04-12 Purdue Research Foundation Re-sensitizing drug-resistant cancer cells by combinational therapy
CN108318311B (zh) * 2017-01-15 2022-01-18 复旦大学 一种硬骨特异性钙质荧光染色方法及其应用
CN106947010B (zh) * 2017-04-06 2018-12-11 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
CN107142281A (zh) * 2017-06-07 2017-09-08 东华大学 聚酰胺‑胺树状大分子与纳米金颗粒的复合物作为非病毒载体进行基因转染的应用方法
CN109554397A (zh) * 2017-09-26 2019-04-02 广州宏柯源生物科技有限公司 纳米颗粒及其制备方法
CN107753946B (zh) * 2017-10-23 2020-11-27 福州大学 一种适配体修饰的靶向载药纳米粒及其制备方法与应用
GB201717975D0 (en) * 2017-10-31 2017-12-13 Cambridge Entpr Ltd Metal organic framework-based compositions and uses thereof
CN111526857B (zh) * 2017-12-21 2023-07-04 H&A帕玛科株式会社 利用金属-有机骨架材料和纳米纤维素的用于透皮递送的复合物
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN108619511B (zh) * 2018-04-20 2020-12-15 山东大学 一种基于阿糖胞苷小分子前药的金属有机框架载药系统的制备方法和应用
CN108794532A (zh) * 2018-05-18 2018-11-13 东北林业大学 脑磷脂类似物、制备方法及用途
CN111110846B (zh) * 2018-10-30 2021-07-23 国家纳米科学中心 一种金属-核酸纳米颗粒及其制备方法和用途
CN111139234B (zh) * 2018-11-06 2022-02-01 举康(上海)生物科技有限公司 一种游离dna提取试剂盒
JP2022501064A (ja) 2018-11-09 2022-01-06 アルブータス・バイオファーマー・コーポレイション ケイ素を含有するカチオン性脂質
WO2020210367A1 (en) * 2019-04-08 2020-10-15 Wisconsin Alumni Research Foundation Ph-responsive silica metal organic framework nanoparticles for delivery of bio active molecules
CN110201160B (zh) * 2019-05-20 2021-12-03 广东医科大学 锆金属有机骨架化合物的制备方法
CN110862546B (zh) * 2019-10-12 2021-07-09 厦门大学 一种甲氨蝶呤金属配位聚合物及其制备方法和应用
US20230001396A1 (en) * 2019-11-14 2023-01-05 Board Of Regents, The University Of Texas System Compositions and methods for controlled delivery and protection of therapeutic agents
WO2021237209A1 (en) * 2020-05-22 2021-11-25 The University Of Chicago Metal-organic frameworks deliver small molecules and biomacromolecules for cancer immunotherapy
US12122921B2 (en) 2020-07-23 2024-10-22 Enzo Biochem, Inc. Fluorescence quencher polymer conjugates and uses thereof
CN115998862B (zh) * 2021-10-21 2025-07-11 北京化工大学 肿瘤特异性酶响应的光动力治疗纳米材料及其制备与应用
CN114099706B (zh) * 2021-11-30 2024-10-01 江南大学 一种用于乳腺癌治疗的mof药物载体及其制备方法
CN114748644B (zh) * 2022-05-20 2023-08-18 齐齐哈尔大学 一种以zif-8为基质的藻蓝蛋白分子印迹药物载体的制备方法
CN115501202B (zh) * 2022-10-12 2023-05-19 北京大学 一种递送过渡态唾液酸转移酶抑制剂的核壳纳米粒子及其制备方法和应用
CN115449088B (zh) * 2022-10-28 2023-06-16 中国人民解放军陆军特色医学中心 一种高孔隙cof纳米颗粒及其制备方法和作为药物载体的应用
CN116212050B (zh) * 2023-03-20 2025-08-08 浙江大学 一种小分子化疗药/生物大分子/金属有机框架复合材料的制备方法及其产品和应用
CN117138055B (zh) * 2023-06-02 2024-04-16 中山大学附属第一医院 一种双载体的阿霉素载药纳米材料及其制备方法
CN116808235A (zh) * 2023-06-27 2023-09-29 安徽瑞拜药业有限公司 一种核酸载体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573914A (zh) * 2009-10-16 2012-07-11 大学健康网络 卟啉纳米囊泡
WO2013009701A2 (en) * 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61351A (en) 1980-10-27 1983-12-30 Yeda Res & Dev Organometallic polymers,their preparation and compositions of co-ordination compounds containing them
US5147806A (en) 1988-04-29 1992-09-15 Igen, Inc. Method and apparatus for conducting electrochemiluminescence measurements
US5213788A (en) 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US5474767A (en) 1990-07-26 1995-12-12 Monsanto Company Polyamines and method for preparation thereof
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5591730A (en) 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US20010003647A1 (en) 1995-06-07 2001-06-14 Ji Sun Coreatant-including electrochemiluminescent compounds, methods, systems and kits utilizing same
US5641623A (en) 1995-01-04 1997-06-24 Martin; Mark T. Electrochemiluminescence assay
US6022737A (en) 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
AU720451B2 (en) 1997-01-24 2000-06-01 Conpharma As Gemcitabine derivatives
US6180082B1 (en) 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US6602932B2 (en) 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
CA2405360A1 (en) 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
WO2002050113A2 (en) 2000-12-21 2002-06-27 Novartis Ag Interleukin-1 related gene and protein
ES2355233T3 (es) 2002-09-28 2011-03-24 Mcneil-Ppc, Inc. Formas de dosificación de liberación modificada con dos núcleos y una abertura.
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
KR100401335B1 (en) 2003-03-08 2003-10-10 Mijitech Co Ltd Metal nanoparticle surface-coated with silicon oxides and preparation thereof
US6878838B2 (en) 2003-03-24 2005-04-12 The University Of North Carolina At Chapel Hill Chiral porous metal phosphonates for heterogeneous asymmetric catalysis
CN100361651C (zh) 2003-03-26 2008-01-16 日本株式会社Ltt生物医药 用于靶向药物送递和持续药物释放的静脉内纳米颗粒
EP1620079A1 (en) 2003-04-03 2006-02-01 Semafore Pharmaceuticals, Inc. Bone targeting of biodegradable drug-containing nanoparticles
MXPA06001004A (es) 2003-07-31 2006-04-27 3M Innovative Properties Co Composiciones para encapsulacion y liberacion controlada.
US20050147963A1 (en) 2003-12-29 2005-07-07 Intel Corporation Composite organic-inorganic nanoparticles and methods for use thereof
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US20070218049A1 (en) 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
JP4992091B2 (ja) 2005-02-17 2012-08-08 ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド 子宮内膜症を治療するためのビスホスホネート
CN1305937C (zh) 2005-02-25 2007-03-21 复旦大学 一种金属配位聚合物纳米结构材料的制备方法
CA2601363A1 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
PE20070360A1 (es) 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20080095699A1 (en) 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
US20070088161A1 (en) 2005-10-19 2007-04-19 Stockel Richard F Novel chelated bisphosphonates for use as pharmaceutical agents
CA2641785C (en) 2006-02-09 2016-05-31 Simon Fraser University Birefringent metal-containing coordination polymers
KR100943923B1 (ko) 2006-03-17 2010-02-24 홍순해 킬레이팅 유기 고분자와 생물학적 금속으로 이루어진 나노입자, 그리고 ｅｐｒ 효과를 이용한 새로운 광범위 무독성항암제 및 그 제조 방법
US20090317335A1 (en) 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
WO2008016172A1 (fr) 2006-08-04 2008-02-07 Kurume University Inhibiteur de métastase
US20080124281A1 (en) 2006-11-29 2008-05-29 Board Of Regents, The University Of Texas System Nanotubular probes as ultrasensitive mr contrast agent
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
US8146682B2 (en) 2007-04-04 2012-04-03 Weatherford/Lamb, Inc. Apparatus and methods of milling a restricted casing shoe
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
FR2921838A1 (fr) 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
WO2009139939A2 (en) 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
WO2009114476A1 (en) * 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising survivin sirna and methods of use thereof
GB0807862D0 (en) 2008-04-29 2008-06-04 Uni I Oslo Compounds
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
SG176528A1 (en) 2009-06-05 2012-01-30 Univ Nanyang Tech Targetted drug delivery to the bone
MX2012005677A (es) 2009-11-20 2012-08-23 Clavis Pharma Asa Formulaciones parentales de derivados de gemcitabina.
GB201013307D0 (en) 2010-08-09 2010-09-22 Univ St Andrews Anti-microbial metal organic framework
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
US20120301537A1 (en) 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
EP2717857B1 (en) 2011-06-06 2018-07-11 University Health Network (UHN) Method for the synthesis of porphyrin-phospholipid conjugates
WO2012174379A2 (en) 2011-06-16 2012-12-20 University Of South Florida Polyhedral cage-containing metalloporphyrin frameworks, methods of making, and methods of using
EP2541220B1 (de) 2011-06-28 2015-04-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung zur Messung einer Temperatur eines Leistungshalbleiters
EP2540321A1 (en) 2011-06-30 2013-01-02 Bayer Intellectual Property GmbH Bis Tridentate W3O2 Clusters for X-Ray imaging
CN102432654A (zh) 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
WO2013068965A2 (en) 2011-11-11 2013-05-16 Koninklijke Philips Electronics N.V. Lighting apparatus and manufacturing method for manufacturing the lighting apparatus
WO2015149072A1 (en) 2014-03-28 2015-10-01 The University Of Chicago Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
US10118169B2 (en) 2014-03-28 2018-11-06 The University Of Chicago Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573914A (zh) * 2009-10-16 2012-07-11 大学健康网络 卟啉纳米囊泡
WO2013009701A2 (en) * 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lipid-coated nanoscale coordination polymers for targeted cisplatin delivery;Rachel C. Huxford-Philips et al.;《RSC Advances》;20130606;第3卷(第34期);14438-14443 *
Modulated Synthesis of Zr‐Based Metal–Organic Frameworks：From Nano to Single Crystals;Andres Schaate et al.;《Chem. Eur. J.》;20110505;第17卷;6643-6651 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872311B2 (en) 2011-07-08 2024-01-16 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof

Also Published As

Publication number Publication date
EP3065713A1 (en) 2016-09-14
US10517822B2 (en) 2019-12-31
JP2020011974A (ja) 2020-01-23
WO2015069926A1 (en) 2015-05-14
US20200085742A1 (en) 2020-03-19
CN105873569A (zh) 2016-08-17
JP2016536318A (ja) 2016-11-24
EP3065713B1 (en) 2024-03-06
EP3065713A4 (en) 2017-07-26
JP6590802B2 (ja) 2019-10-16
US20160346204A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CN105873569B (zh) 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体
Wang et al. Endosomolytic and tumor-penetrating mesoporous silica nanoparticles for siRNA/miRNA combination cancer therapy
Yang et al. Biodegradable polymer-coated multifunctional graphene quantum dots for light-triggered synergetic therapy of pancreatic cancer
Feng et al. Charge-convertible carbon dots for imaging-guided drug delivery with enhanced in vivo cancer therapeutic efficiency
Fernandez-Piñeiro et al. Nanocarriers for microRNA delivery in cancer medicine
Lee et al. Recent developments in nanoparticle‐based siRNA delivery for cancer therapy
Tu et al. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape
Devulapally et al. Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes
Li et al. Nanoparticle delivery systems for siRNA-based therapeutics
Chen et al. A pH-responsive cyclodextrin-based hybrid nanosystem as a nonviral vector for gene delivery
Moghadam et al. Graphene family in cancer therapy: recent progress in cancer gene/drug delivery applications
Ubanako et al. Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Játiva et al. Use of nanoparticles for glioblastoma treatment: a new approach
Gozuacik et al. Anticancer use of nanoparticles as nucleic acid carriers
KR20130066521A (ko) 유전자 나노 복합체 및 이를 이용한 유전자의 세포 내재화 방법
Wahane et al. Dual-modality poly-L-histidine nanoparticles to deliver peptide nucleic acids and paclitaxel for in vivo cancer therapy
George et al. Advances in nanotechnology-based platforms for survivin-targeted drug discovery
Han et al. DNA as highly biocompatible carriers for drug delivery
Hu et al. Nanocarriers for cutting-edge cancer immunotherapies
Hou et al. Tumor targeted and GSH stimuli-response α‑lactalbumin nanotubes co-delivering doxorubicin and siRNA for cancer therapy
CN107007550A (zh) 一种氧化还原响应性两亲性共聚物及其制备方法和应用
Pircalabioru et al. Nanodrug delivery systems in cancer
Sharma et al. Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer
CHEMOTHERAPEUTICS c12) United States Patent
Karaca et al. Targeted delivery systems for treatment of pancreatic cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant